- Trials with a EudraCT protocol (35)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (17)
35 result(s) found for: Eosin.
Displaying page 1 of 2.
EudraCT Number: 2005-000175-17 | Sponsor Protocol Number: 1100.1448 | Start Date*: 2005-05-31 |
Sponsor Name: [...] | ||
Full Title: A pharmacokinetic study to assess Nevirapine levels in HIV-infected patients with impaired hepatic function. | ||
Medical condition: Treatment of HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-002478-29 | Sponsor Protocol Number: CA224-063 | Start Date*: 2019-11-27 | |||||||||||
Sponsor Name:University Hospital Essen | |||||||||||||
Full Title: Neoadjuvant nivolumab combination treatment in resectable non-small cell lung cancer patients: Defining optimal combinations and determinants of immunological response (NEOpredict-Lung) | |||||||||||||
Medical condition: non-small cell lung cancer (NSCLC) of clinical stages IB, II and selected stage III A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004190-13 | Sponsor Protocol Number: TX05-03 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Tanvex Biologics Corp. | |||||||||||||
Full Title: A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer | |||||||||||||
Medical condition: HER-2 positive breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004397-96 | Sponsor Protocol Number: CF20112018 | Start Date*: 2019-04-09 | |||||||||||
Sponsor Name:Merete Hædersdal | |||||||||||||
Full Title: Impact of thermo-mechanical intervention on Protoporphyrin IX accumulation and biodistribution in normal skin following topical 5-aminolevulinic acid at high and low vehicle viscosity | |||||||||||||
Medical condition: Healthy skin on the upper back on 3 participants in study a and 12 participants in study b. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024532-42 | Sponsor Protocol Number: CLIFE-010FV | Start Date*: 2011-06-30 | |||||||||||
Sponsor Name:María José Linares Gil | |||||||||||||
Full Title: Ensayo multicéntrico aleatorizado a doble ciego, para evaluar la eficacia analgésica y la seguridad del gel de Lidocaína+Diclofenaco tópico (300mg+90mg)frente la lidocaina sóla (300mg) en la Cirug... | |||||||||||||
Medical condition: Dolor postoperatoorio de la cirugía anorectal benigna | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003922-27 | Sponsor Protocol Number: PAM-UMCG-002 | Start Date*: 2024-02-08 |
Sponsor Name:University Medical Center Groningen (UMCG) | ||
Full Title: Neo-adjuvant Pembrolizumab as alternative to radio(chemo)therapy in MMRd uterine cancer | ||
Medical condition: Primary uterine cancer characterized with dMMR | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001868-11 | Sponsor Protocol Number: PELICAN-IPC2015-016 | Start Date*: 2017-09-08 | |||||||||||
Sponsor Name:Institut Paoli Calmettes | |||||||||||||
Full Title: A prospective, multicentre, open-label, randomized, phase II study of Pembrolizumab in combination with neoadjuvante (F)EC-Paclitaxel regimen in HER2-negative inflammatory breast cancer. | |||||||||||||
Medical condition: Inflammatory breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-004305-24 | Sponsor Protocol Number: BCCItraconazole | Start Date*: 2012-04-18 | ||||||||||||||||
Sponsor Name:Med Uni Graz, Univ. Klinik Dermatologie,Abteilung für Allgemeine Dermatologie | ||||||||||||||||||
Full Title: Inhibition of the Hedgehog Pathway in Basal Cell Carcinomas of Patients treated with Itraconazole for Onychomycosis | ||||||||||||||||||
Medical condition: Basal cell carcinoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: AT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002383-27 | Sponsor Protocol Number: CHDR1806 | Start Date*: 2019-08-01 | |||||||||||
Sponsor Name:Centre for Human Drug Research | |||||||||||||
Full Title: An exploratory, single-center, double-blinded, healthy volunteer controlled study to characterize psoriasis patients and explore novel biomarkers for the treatment response of psoriasis with a mult... | |||||||||||||
Medical condition: Psoriasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002147-28 | Sponsor Protocol Number: CT-P16_3.1 | Start Date*: 2018-12-10 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non... | |||||||||||||
Medical condition: Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) HU (Completed) BG (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004525-84 | Sponsor Protocol Number: CT-P6-3.2 | Start Date*: 2014-04-03 | |||||||||||
Sponsor Name:CELLTRION, Inc. | |||||||||||||
Full Title: A Phase 3, Double-Blind, Randomized, Parallel-Group, Active-Controlled Study to Compare the Efficacy and Safety of CT-P6 and Herceptin as Neoadjuvant and Adjuvant Treatment in Patients with HER2-Po... | |||||||||||||
Medical condition: Her-2 Positive Early Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: LV (Completed) GR (Completed) HU (Completed) ES (Completed) IT (Completed) PT (Completed) RO (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002704-34 | Sponsor Protocol Number: HGS1008-C1067 | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... | |||||||||||||
Medical condition: Chronic Hepatitis C (CHC) genotype 2/3. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FR (Completed) SE (Completed) GB (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002703-13 | Sponsor Protocol Number: HGS1008-C1060 | Start Date*: 2007-03-20 | |||||||||||
Sponsor Name:Human Genome Sciences, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or P... | |||||||||||||
Medical condition: Chronic hepatitis C (CHC) genotype 1. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) CZ (Completed) AT (Completed) FR (Completed) GB (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002745-38 | Sponsor Protocol Number: GEIS-30 | Start Date*: 2012-10-22 | ||||||||||||||||
Sponsor Name:Grupo Español de Investigación en Sarcomas | ||||||||||||||||||
Full Title: Phase II Clinical Trial of Pazopanib to evaluate the activity and tolerability in patients with advanced and/or metastatic liposarcoma who have relapsed following standard therapies or for whom no ... | ||||||||||||||||||
Medical condition: Advanced and/or metastatic liposarcoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-004456-30 | Sponsor Protocol Number: B9991030 | Start Date*: 2018-09-13 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH... | |||||||||||||
Medical condition: PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) BE (Completed) GB (GB - no longer in EU/EEA) EE (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001861-40 | Sponsor Protocol Number: BRTA-0100-015 (EORTC 62061) | Start Date*: 2006-09-21 | |||||||||||
Sponsor Name:SYSTEMS MEDICINE, LLC | |||||||||||||
Full Title: Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma | |||||||||||||
Medical condition: Advanced or metastatic soft tissue sarcoma. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) GB (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002892-80 | Sponsor Protocol Number: MedOPP100 | Start Date*: 2018-03-22 | |||||||||||
Sponsor Name:Medica Scientia Innovation Research (MedSIR) | |||||||||||||
Full Title: A two-stage Simon Design phase II study for NOn-BRCA metastatic BReast cancer (MBC) patients with homologous recombination deficiency treated with OLAparib single agent (NOBROLA study) | |||||||||||||
Medical condition: Metastatic breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Restarted) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001083-38 | Sponsor Protocol Number: GISG-15 | Start Date*: 2018-03-14 | |||||||||||||||||||||||||||||||
Sponsor Name:Universitätsmedizin Greifswald | |||||||||||||||||||||||||||||||||
Full Title: Combined treatment with Nivolumab and Trabectedin in patients with metastatic or inoperable soft tissue Sarcomas - The NiTraSarc Phase II Trial | |||||||||||||||||||||||||||||||||
Medical condition: metastatic or inoperable soft tissue sarcoma | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002806-28 | Sponsor Protocol Number: SOLTI-1502 | Start Date*: 2019-10-25 |
Sponsor Name:SOLTI | ||
Full Title: TARGETING THE PAM50 HER2-ENRICHED PHENOTYPE WITH ENZALUTAMIDE IN HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE METASTATIC BREAST CANCER | ||
Medical condition: Male or pre/post-menopausal women age ≥ 18 years with advanced HR+/HER2-negative locally advanced/metastatic breast cancer resistant to endocrine therapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005792-12 | Sponsor Protocol Number: GOIRC-06-2020 | Start Date*: 2022-04-05 | |||||||||||
Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA CLINICA (GOIRC) | |||||||||||||
Full Title: Pilot ‘Window of Opportunity’ Neoadjuvant Study of Abemaciclib in Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) | |||||||||||||
Medical condition: Low-Estrogen Receptor (ER) positive/Human Epidermal Growth Factor Receptor 2 (HER2)-negative Early Breast Cancer (BC) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
